Skipping Hormone Therapy in Low-Risk Early Breast Cancer (NoELA)
No Endocrine Therapy in Small HR⁺/HER2- Low Risk Luminal A Early Breast Cancer, a Single-arm De-escalation Trial
The goal of this clinical trial is to determine whether a selected population of women with early-stage, low-risk breast cancer can avoid hormone therapy without increasing their risk of relapse. It will also evaluate the prognosis of these participants compared to participants who received standard treatment with hormone therapy in another study, estimate the risk of specific recurrence, cardiovascular and bone health, and participants' quality of life.
All participants will have undergone surgery and possibly radiation therapy, but unlike standard care, they will not receive hormone therapy afterward. Participants will be enrolled for two years and followed for up to five years after the last participant is enrolled in the trial to monitor for long-term cancer recurrence.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Breast cancer is the most frequently diagnosed cancer among women worldwide. Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) tumors represent the predominant subtype and are generally associated with favorable outcomes. Adjuvant endocrine therapy (ET), including tamoxifen and aromatase inhibitors, constitutes a cornerstone of treatment for HR+/HER2- early breast cancer and has demonstrated reductions in recurrence and mortality in large randomized trials and meta-analyses. However, these benefits were mainly established in populations including patients with a broader spectrum of recurrence risk.
The implementation of mammography screening programs has increased the detection of small, early-stage breast cancers, including tumors with excellent prognosis and very low risk of recurrence. In postmenopausal women with small node-negative Luminal A tumors, recurrence rates are particularly low, raising concerns regarding potential overtreatment and the balance between treatment benefit and toxicity.
Although ET is effective, its long-term administration is associated with substantial treatment burden and persistent toxicities, including musculoskeletal symptoms, vasomotor symptoms, fatigue, sexual dysfunction, mood disturbances, and bone loss. These adverse effects may significantly affect quality of life and contribute to treatment discontinuation. Observational data have suggested that ET-related quality-of-life impairment may persist longer than chemotherapy-related effects, particularly in postmenopausal women.
Retrospective studies have suggested that the absolute benefit of ET may be limited in selected patients with very low-risk disease, especially among older women with small, low-grade HR+/HER2- tumors. Furthermore, simulation models estimating individualized treatment benefit indicate that the absolute overall survival gain associated with ET in some low-risk subgroups may be minimal, with high numbers needed to treat.
Advances in biological characterization have enabled identification of Luminal A tumors, characterized by strong hormone receptor expression, low proliferative activity, and favorable prognosis. Combining biological characteristics with clinicopathological features such as age, tumor size, grade, and nodal status allows the identification of a subgroup of postmenopausal patients with exceptionally low risk of relapse.
NoELA was developed to prospectively evaluate a therapeutic de-escalation strategy consisting of omission of adjuvant ET in postmenopausal women presenting with very low-risk HR+/HER2- early breast cancer with Luminal A phenotype. The study focuses on patients expected to derive limited benefit from ET while remaining exposed to its long-term toxicity burden.
The study also aims to generate evidence supporting more individualized treatment strategies and improved shared decision-making by better quantifying the risk-benefit balance of ET omission in this population. In addition, comparison with external real-world data derived from patients treated with standard ET will help contextualize outcomes and improve the external validity of the findings.
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Unicancer Project Leader
- Telefoonnummer: 0033 6 58 43 58 94
- E-mail: a-poitou@unicancer.fr
Studie Locaties
-
-
-
Angers, Frankrijk
- Nog niet aan het werven
- ICO Angers
-
Contact:
- Dr PATSOURIS
-
Avignon, Frankrijk
- Nog niet aan het werven
- Sainte Catherine, Institut du Cancer Avignon-Provence
-
Contact:
- Dr GRENIER
-
Bayeux, Frankrijk
- Nog niet aan het werven
- Ch Aunay-Bayeux
-
Contact:
- Dr BRACHET
-
Bayonne, Frankrijk
- Nog niet aan het werven
- CHCB
-
Contact:
- Dr GRELLETY
-
Bordeaux, Frankrijk
- Nog niet aan het werven
- Institut Bergonie
-
Contact:
- Dr PETIT
-
Bordeaux, Frankrijk
- Nog niet aan het werven
- Clinique Tivoli
-
Contact:
- Dr GARBAY
-
Boulogne-sur-Mer, Frankrijk
- Nog niet aan het werven
- CH Boulogne sur Mer
-
Contact:
- Dr DESGROUSILLIERS
-
Brest, Frankrijk
- Nog niet aan het werven
- Clinique Pasteur Lanroze
-
Contact:
- Dr LENGLET
-
Briis-sous-Forges, Frankrijk
- Nog niet aan het werven
- CH de Bligny
-
Contact:
- Dr MERIC
-
Caen, Frankrijk
- Nog niet aan het werven
- Centre François Baclesse
-
Contact:
- Dr EMILE
-
Chambray-lès-Tours, Frankrijk
- Nog niet aan het werven
- Pole Sante Leonard de Vinci- Roc37
-
Contact:
- Dr BERNADOU
-
Clermont-Ferrand, Frankrijk
- Nog niet aan het werven
- Centre Jean Perrin
-
Contact:
- Dr MOURET-REYNIER
-
Dechy, Frankrijk
- Nog niet aan het werven
- Centre Leonard de Vinci
-
Contact:
- Dr ESCANDE
-
Dijon, Frankrijk
- Nog niet aan het werven
- Centre Georges François Leclerc
-
Contact:
- Pr LADOIRE
-
La Roche-sur-Yon, Frankrijk
- Nog niet aan het werven
- CHD Vendée
-
Contact:
- Dr LEGOUTE
-
Le Havre, Frankrijk
- Actief, niet wervend
- Centre Guillaume Le Conquérant
-
Lille, Frankrijk
- Actief, niet wervend
- Centre Oscar Lambret
-
Limoges, Frankrijk
- Nog niet aan het werven
- CHU de Limoges
-
Contact:
- Pr DELUCHE
-
Lorient, Frankrijk
- Werving
- Groupe Hospitalier Bretagne Sud
-
Contact:
- Dr BERTHET
-
Lyon, Frankrijk
- Nog niet aan het werven
- Hôpital privé Jean Mermoz
-
Contact:
- Dr DERBEL
-
Lyon, Frankrijk
- Actief, niet wervend
- Centre Léon Bérard
-
Marseille, Frankrijk
- Nog niet aan het werven
- Institut Paoli-Calmettes
-
Contact:
- Pr GONCALVES
-
Marseille, Frankrijk
- Nog niet aan het werven
- Hôpital Privé Clairval
-
Contact:
- Dr PAOLI
-
Mont-de-Marsan, Frankrijk
- Actief, niet wervend
- CHI de Mont-de-Marsan
-
Nice, Frankrijk
- Nog niet aan het werven
- Centre Antoine Lacassagne
-
Contact:
- Dr GROULIER
-
Orléans, Frankrijk
- Nog niet aan het werven
- Chu Orleans
-
Contact:
- Dr TOROSSIAN
-
Osny, Frankrijk
- Nog niet aan het werven
- CHP Sainte Marie
-
Contact:
- Dr BLEICHNER
-
Paris, Frankrijk
- Nog niet aan het werven
- Groupe hospitalier Paris saint Joseph
-
Contact:
- Dr SIMONAGGIO
-
Paris, Frankrijk
- Actief, niet wervend
- Institut Curie
-
Rennes, Frankrijk
- Nog niet aan het werven
- Centre Eugene Marquis
-
Contact:
- Dr PERRIN
-
Rouen, Frankrijk
- Nog niet aan het werven
- Centre Henri Becquerel
-
Contact:
- Dr VITUCCI
-
Saint-Cloud, Frankrijk
- Nog niet aan het werven
- Institut Curie
-
Contact:
- Dr BELLO ROUFAI
-
Saint-Herblain, Frankrijk
- Nog niet aan het werven
- Ico Saint Herblain
-
Contact:
- Dr FRENEL
-
Saint-Priest-en-Jarez, Frankrijk
- Nog niet aan het werven
- CHU de Saint Etienne
-
Contact:
- Dr CORSINI
-
Strasbourg, Frankrijk
- Nog niet aan het werven
- Centre de lutte contre le cancer - Paul Strauss
-
Contact:
- Dr BISCHOFF
-
Thonon-les-Bains, Frankrijk
- Nog niet aan het werven
- Hopitaux du Leman
-
Contact:
- Dr CIOBANU
-
Toulouse, Frankrijk
- Nog niet aan het werven
- IUCT-Oncopole
-
Contact:
- Pr DALENC
-
Tours, Frankrijk
- Nog niet aan het werven
- CHU Tours
-
Contact:
- Dr LARRIVIERE
-
Vandœuvre-lès-Nancy, Frankrijk
- Nog niet aan het werven
- Institut de Cancérologie de Lorraine
-
Contact:
- Dr CHARRA-BRUNAUD
-
Vantoux, Frankrijk
- Nog niet aan het werven
- Groupe UNEOS-Hôpital Robert Schuman
-
Contact:
- Dr BENNA
-
Épagny, Frankrijk
- Actief, niet wervend
- CH Annecy Genevois
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Postmenopausal (underwent bilateral oophorectomy or non-chemo induced amenorrhea for 12 or more months) female participant ≥60 years of age.
- New diagnosis of invasive carcinoma of the breast (ductal, tubular or mucinous) with primary tumor ≤1 cm on microscopic exam with no evidence of nodal or distant metastatic disease.
- Contralateral breast described as BI-RADS (Breast Imaging-Reporting And Data System) 1 or 2 in diagnostic imaging.
- Negative axillary node involvement by sentinel node biopsy or axillary node dissection (pN0) or Clinically negative axillary node involvement (cN0) after mandatory ultrasound exploration without surgical exploration of the axilla if Breast Conservative Surgery (BCS) was performed.
- Estrogen Receptor (ER) positive (≥ 50%) and Progesterone Receptor(PR) positive (> 20%), Ki67 low (≤15%) and HER2 negative (IHC or In Situ Hybridization approach) according to ASCO (American Society of Clinical Oncology) criteria.
- Histological grade scored on the invasive component, 1 or 2 if pT1a or grade 1 if pT1b.
- Treated by mastectomy or BCS with microscopically clear resection margins defined as "no-ink on tumor" or ≥1 mm for invasive and non-invasive disease or no residual disease on re-excision.
- If BCS was performed, participants must have received or have scheduled adjuvant local radiotherapy (RT) within 3 months after surgery
- No indication of adjuvant chemotherapy.
- The participant is willing and able to comply with the protocol for the duration of the study, including scheduled visits, treatment strategy, laboratory tests and other study procedures.
- Participants must be affiliated with a Social Security System (or equivalent).
- The participant must have signed a written informed consent form before any trial-specific procedures. When the participant is physically unable to give written consent, an impartial witness of her choice, independent from the investigator or the sponsor, can confirm the participant's consent in writing.
Exclusion Criteria:
- Have received any neo-adjuvant treatment, including hormone therapy and chemotherapy.
- Have received or are eligible for adjuvant chemotherapy.
- Absolute contraindication for RT in case of BCS or patients who were treated with partial breast irradiation.
- Have been treated with mastectomy and with adjuvant radiotherapy received or scheduled.
- Invasive lobular breast cancer.
- Bilateral breast cancer or history of other invasive ipsi- or contralateral breast cancer.
- Multifocal or multicentric disease.
- Disease limited to microinvasion only (< 1 mm).
- Evidence of lymphovascular invasion.
- History of non-breast cancer malignancies if not disease-free for > 5 years and considered low risk of recurrence except for treated carcinoma in situ of the cervix, endometrium or colon, melanoma in situ and basal or squamous cell carcinoma of the skin.
- Non-malignant severe disease associated with a life expectancy < 10 years.
- Women with BRCA1, BRCA2 or other high-risk breast cancer predisposing deleterious germline mutations.
- Enrolled in another therapeutic study within 30 days prior to inclusion.
- Unwilling or unable to comply with the medical follow-up required by the trial because of geographic, familial, social, or psychological reasons.
- Persons deprived of their liberty or under protective custody or guardianship.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: No Endocrine Therapy
The endocrine therapy will not be received by the participant during the study.
|
The standard of care endocrine therapy (Tamoxifene, Letrozole, Anastrozole or Exemestane) will not be received by the participant during the study.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Relapse-free interval
Tijdsspanne: At 5 years after the last treatment
|
Relapse-free interval (RFI) is defined as the delay between initial treatment and the first occurrence of i) ipsilateral breast tumor recurrence, ii) distant or locoregional recurrence or iii) death from breast cancer, according to the STEEP system definition version 2.0 (Tolaney SM et al., J Clin Oncol 2021)
|
At 5 years after the last treatment
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidence of Ipsilateral Ductal Carcinoma In Situ (DCIS)
Tijdsspanne: At 5 years after the last treatment
|
At 5 years after the last treatment
|
|
|
Incidence of invasive contralateral breast cancer
Tijdsspanne: At 5 years after the last treatment
|
At 5 years after the last treatment
|
|
|
Distant disease free survival (DDFS)
Tijdsspanne: At 5 years after the last treatment
|
Distant disease free survival is defined as the delay between date of inclusion and distant tumor relapse or death from any cause, whichever occurs first.
|
At 5 years after the last treatment
|
|
Relapse free survival (RFS)
Tijdsspanne: 5 years after the last treatment
|
Relapse-free survival is defined as the delay between date of inclusion and tumor relapse (local, regional, or distant) or death from any cause, whichever occurs first.
|
5 years after the last treatment
|
|
Overall survival (OS)
Tijdsspanne: At 5 years after the last treatment
|
The overall survival is the length of time from randomization that patients enrolled in the study are still alive.
|
At 5 years after the last treatment
|
|
Quality of life questionnaire - Core 30 (QLQ-C30)
Tijdsspanne: At baseline, 6 months, 1 year, and then annually until 5 years after the last inclusion
|
Developed by the EORTC, this self-reported questionnaire assesses the health-related quality of life of cancer patients in clinical trials. The questionnaire includes five functional scales (physical, everyday activity, cognitive, emotional, and social), three symptom scales (fatigue, pain, nausea and vomiting), a health/quality of life overall scale, and a number of additional elements assessing common symptoms (including dyspnea, loss of appetite, insomnia, constipation, and diarrhea), as well as, the perceived financial impact of the disease. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. |
At baseline, 6 months, 1 year, and then annually until 5 years after the last inclusion
|
|
Quality of Life Questionnaire - Breast cancer module (QLQ-BR42)
Tijdsspanne: At baseline, 6 months, 1 year, and then annually until 5 year after the last inclusion
|
This EORTC breast cancer specific questionnaire is intended to supplement the QLQ-C30. The QLQ-BR42 incorporates nine multi-item scales to assess body image, sexual functioning, breast satisfaction, systemic therapy side effects, arm symptoms, breast symptoms, endocrine therapy symptoms, skin mucosis symptoms, endocrine sexual symptoms. In addition, single items assess sexual enjoyment, future perspective and being upset by hair loss. All items are rated on a four-point Likert-type scale (1 = "not at all", 2 = "a little", 3 = "quite a bit", and 4 = "very much"), and are linearly transformed to a 0-100 scale. Higher scores indicate more severe symptoms or problems for all items. |
At baseline, 6 months, 1 year, and then annually until 5 year after the last inclusion
|
|
Hospital anxiety and depression scale (HADS)
Tijdsspanne: At baseline, 6 months, 1 year, and then annually until 5 year after the last inclusion
|
The HADS is a 14 items questionnaire: 7 items related to anxiety and 7 items related to depression scored on a scale.
Scores for items in each subscale of the HADS are summed to produce an anxiety score (HADS-A) or a depression score (HADS-D), or can be added to produce a total score corresponding to emotional distress (HADS-T).
Each item is rated on a 4-point Likert scale (1 = "not at all", 2 = "a little", 3 = "quite a bit", and 4 = "very much"), for a total score ranging from 0-21 for each subscale.
The entire scale (emotional distress) range from 0 to 42, with higher scores indicating more distress.
|
At baseline, 6 months, 1 year, and then annually until 5 year after the last inclusion
|
|
Bone-related events and osteopenia/osteoporosis diagnosis, dyslipidemia (hypercholesterolemia and hypertriglyceridemia) and cardiovascular events (myocardial infarction, stroke, and thromboembolic events), as per CTCAE v6.0
Tijdsspanne: Throughout study completion, up to 5 years after the last inclusion
|
The National Cancer Institute-Common Terminology Criteria for Adverse Events version 6 (NCI-CTCAE v6) is widely accepted in the community of oncology research as the leading rating scale for adverse events.
This scale, divided into 5 grades (1 = "mild", 2 = "moderate", 3 = "severe", 4 = "life-threatening", and 5 = "death") determined by the investigator, will make it possible to assess the severity of the disorders.
|
Throughout study completion, up to 5 years after the last inclusion
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Jean-Yves PIERGA, MD, Institut Curie
- Hoofdonderzoeker: José Luis SANDOVAL, MD, University Hospital, Geneva
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- UC-BCG-2513
- 2025-523683-20-00 (Ctis)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .